ClinicalTrials.gg
CompletedNCT05952869Updated Feb 24, 2026Results posted

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)

A Phase 3 interventional study of Enlicitide Decanoate and Placebo in Hypercholesterolemia and Familial Hypercholesterolemia, sponsored by Merck Sharp & Dohme LLC. Completed at 59 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
303
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Hypercholesterolemia by Merck & Co., Inc — 1 open to participants now, 3 under way, 3 of them phase 3. Hypercholesterolemia · Merck & Co., Inc.

Enrollment
19th of 27
303 · median 500
Started
2023
with 3 others
Phase 3
17 of 29
1 open now
Registered
22nd of 29
by date

Among the 29 studies in Hypercholesterolemia by Merck & Co., Inc, this one is the 19th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2023, is one of 17 in phase 3, and was the 22nd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 29 studies in Hypercholesterolemia by Merck & Co., Inc is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Hypercholesterolemia by Merck & Co., Inc, or all of them as a file.
02

Study summary

The goal of this study is to evaluate the efficacy, safety, and tolerability of enlicitide decanoate in adult participants with heterozygous familial hypercholesterolemia. The primary hypothesis is that enlicitide decanoate is superior to placebo on mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 24.

03

Conditions studied

  • Hypercholesterolemia
  • Familial Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has possible or definite diagnosis of heterozygous familial hypercholesterolemia (HeFH) based on a locally accepted diagnostic algorithm
  • Has an LDL-C ≥55 mg/dL or ≥70 mg/dL depending on medical history
  • Is treated with a moderate- or high-intensity statin medication
  • Is on a stable dose of all background lipid-lowering therapies (LLTs) with no planned medication change

Exclusion criteria

Exclusion Criteria:

  • Has a history of homozygous familial hypercholesterolemia (FH) based on genetic or clinical criteria, compound heterozygous FH, or double heterozygous FH
  • Has a history of heart failure or heart failure hospitalization within 3 months before first study visit
  • Is undergoing or previously underwent an LDL-C apheresis program within 3 months before first study visit or plans to initiate an LDL-C apheresis program
  • Was previously treated/is being treated with certain other cholesterol lowering medications, including protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
303 participants (actual)

Study arms

  • Experimental
    Enlicitide Decanoate

    Participants received 20 mg of enlicitide decanoate orally once daily (QD) for up to 52 weeks.

    Drug: Enlicitide Decanoate

  • Placebo comparator
    Placebo

    Participants received enlicitide decanoate-matching placebo orally QD for up to 52 weeks.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24

    Blood samples were collected at baseline and at Week 24 to determine mean percent change in LDL-C. The two treatment groups were compared using an analysis of covariance model with treatment as a fixed effect and baseline LDL-C as a covariate.

    Time frame: Baseline and Week 24

  2. Number of Participants With Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 64 weeks (8 weeks postdose)

  3. Number of Participants Who Discontinued Study Drug Due to an AE

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 56 weeks

Secondary outcomes

  1. Mean Percent Change From Baseline in LDL-C at Week 52

    Blood samples were collected at baseline and at Week 52 to determine mean percent change in LDL-C. The two treatment groups were compared using an analysis of covariance model with treatment as a fixed effect and baseline LDL-C as a covariate.

    Time frame: Baseline and Week 52

  2. Mean Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (HDL-C) at Week 24

    Blood samples were collected at baseline and at Week 24 to determine mean percent change in non-HDL-C. The two treatment groups were compared using an analysis of covariance model with treatment as a fixed effect and baseline non-HDL-C as a covariate.

    Time frame: Baseline and Week 24

  3. Mean Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 24

    Blood samples were collected at baseline and at Week 24 to determine mean percent change in ApoB. The two treatment groups were compared using an analysis of covariance model with treatment as a fixed effect and baseline ApoB as a covariate.

    Time frame: Baseline and Week 24

  4. Percent Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 24

    Blood samples were collected at baseline and at Week 24 to determine percent change in Lp(a). For percent change in Lp(a) at Week 24, the two treatment groups were analyzed using the Wilcoxon signed rank test with Hodges-Lehmann estimation.

    Time frame: Baseline and Week 24

  5. Percentage of Participants With LDL-C <70 mg/dL and ≥50% Reduction From Baseline at Week 24

    Blood samples were collected at baseline and at Week 24 to determine the percentage of participants who had LDL-C \<70 mg/dL and ≥50% reduction from baseline. The two treatment groups were analyzed based on the Miettinen and Nurminen method for the difference in percentage.

    Time frame: Baseline and Week 24

  6. Percentage of Participants With LDL-C <55 mg/dL and ≥50% Reduction From Baseline at Week 24

    Blood samples were collected at baseline and at Week 24 to determine the percentage of participants who had LDL-C \<55 mg/dL and ≥50% reduction from baseline. The two treatment groups were analyzed based on the Miettinen and Nurminen method for the difference in percentage.

    Time frame: Baseline and Week 24

07

Results

Posted Feb 24, 2026

Participant flow

Participant flow — Overall Study
MilestoneEnlicitide DecanoatePlacebo
Started202101
Completed19697
Not completed64
Withdrew: Withdrawal by subject53
Withdrew: Lost to follow-up01
Withdrew: Death10

Outcome measures

PrimaryMean Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24

Blood samples were collected at baseline and at Week 24 to determine mean percent change in LDL-C. The two treatment groups were compared using an analysis of covariance model with treatment as a fixed effect and baseline LDL-C as a covariate.

Time frame:
Baseline and Week 24
Reported as:
Mean · Percent Change
Mean Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24
Percent ChangeEnlicitide DecanoatePlacebo
Mean Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24-58.2 ± 28.02.6 ± 23.6
Statistical analysis
  • Enlicitide Decanoate vs Placebo · ANCOVA · p = <0.001 · Difference in means: -59.4 · 95% CI -65.6 to -53.2
PrimaryNumber of Participants With Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to 64 weeks (8 weeks postdose)
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsEnlicitide DecanoatePlacebo
Number of Participants With Adverse Events (AEs)15777
PrimaryNumber of Participants Who Discontinued Study Drug Due to an AE

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to 56 weeks
Reported as:
Number · Participants
Number of Participants Who Discontinued Study Drug Due to an AE
ParticipantsEnlicitide DecanoatePlacebo
Number of Participants Who Discontinued Study Drug Due to an AE43
SecondaryMean Percent Change From Baseline in LDL-C at Week 52

Blood samples were collected at baseline and at Week 52 to determine mean percent change in LDL-C. The two treatment groups were compared using an analysis of covariance model with treatment as a fixed effect and baseline LDL-C as a covariate.

Time frame:
Baseline and Week 52
Reported as:
Mean · Percent Change
Mean Percent Change From Baseline in LDL-C at Week 52
Percent ChangeEnlicitide DecanoatePlacebo
Mean Percent Change From Baseline in LDL-C at Week 52-55.3 ± 27.98.7 ± 33.0
Statistical analysis
  • Enlicitide Decanoate vs Placebo · ANCOVA · p = <0.001 · Difference in means: -61.5 · 95% CI -69.4 to -53.7
SecondaryMean Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (HDL-C) at Week 24

Blood samples were collected at baseline and at Week 24 to determine mean percent change in non-HDL-C. The two treatment groups were compared using an analysis of covariance model with treatment as a fixed effect and baseline non-HDL-C as a covariate.

Time frame:
Baseline and Week 24
Reported as:
Mean · Percent Change
Mean Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (HDL-C) at Week 24
Percent ChangeEnlicitide DecanoatePlacebo
Mean Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (HDL-C) at Week 24-52.3 ± 26.92.1 ± 20.5
Statistical analysis
  • Enlicitide Decanoate vs Placebo · ANCOVA · p = <0.001 · Difference in means: -53.0 · 95% CI -58.5 to -47.4
SecondaryMean Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 24

Blood samples were collected at baseline and at Week 24 to determine mean percent change in ApoB. The two treatment groups were compared using an analysis of covariance model with treatment as a fixed effect and baseline ApoB as a covariate.

Time frame:
Baseline and Week 24
Reported as:
Mean · Percent Change
Mean Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 24
Percent ChangeEnlicitide DecanoatePlacebo
Mean Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 24-48.2 ± 23.61.8 ± 17.5
Statistical analysis
  • Enlicitide Decanoate vs Placebo · ANCOVA · p = <0.001 · Difference in means: -49.1 · 95% CI -54.0 to -44.3
SecondaryPercent Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 24

Blood samples were collected at baseline and at Week 24 to determine percent change in Lp(a). For percent change in Lp(a) at Week 24, the two treatment groups were analyzed using the Wilcoxon signed rank test with Hodges-Lehmann estimation.

Time frame:
Baseline and Week 24
Reported as:
Median · Percent Change
Percent Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 24
Percent ChangeEnlicitide DecanoatePlacebo
Percent Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 24-24.7 (-78.1 to 170.6)-1.6 (-47.4 to 67.0)
Statistical analysis
  • Enlicitide Decanoate vs Placebo · Wilcoxon based on Hodges & Lehmann. · p = <0.001 (P-value was obtained via the aligned rank Wilcoxon test.) · Difference in medians: -27.5 · 95% CI -34.3 to -20.6Wilcoxon signed rank test with Hodges-Lehmann estimation
SecondaryPercentage of Participants With LDL-C <70 mg/dL and ≥50% Reduction From Baseline at Week 24

Blood samples were collected at baseline and at Week 24 to determine the percentage of participants who had LDL-C \<70 mg/dL and ≥50% reduction from baseline. The two treatment groups were analyzed based on the Miettinen and Nurminen method for the difference in percentage.

Time frame:
Baseline and Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants With LDL-C <70 mg/dL and ≥50% Reduction From Baseline at Week 24
Percentage of ParticipantsEnlicitide DecanoatePlacebo
Percentage of Participants With LDL-C <70 mg/dL and ≥50% Reduction From Baseline at Week 2470.81.0
Statistical analysis
  • Enlicitide Decanoate vs Placebo · Miettinen and Nurminen method. · p = <0.001 · Difference in percentage: 69.8 · 95% CI 62.6 to 75.9
SecondaryPercentage of Participants With LDL-C <55 mg/dL and ≥50% Reduction From Baseline at Week 24

Blood samples were collected at baseline and at Week 24 to determine the percentage of participants who had LDL-C \<55 mg/dL and ≥50% reduction from baseline. The two treatment groups were analyzed based on the Miettinen and Nurminen method for the difference in percentage.

Time frame:
Baseline and Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants With LDL-C <55 mg/dL and ≥50% Reduction From Baseline at Week 24
Percentage of ParticipantsEnlicitide DecanoatePlacebo
Percentage of Participants With LDL-C <55 mg/dL and ≥50% Reduction From Baseline at Week 2467.31.0
Statistical analysis
  • Enlicitide Decanoate vs Placebo · Miettinen and Nurminen method. · p = <0.001 · Difference in percentage: 66.3 · 95% CI 59.1 to 72.6

Adverse events

Collected over Up to 64 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enlicitide Decanoate1/202 (0.5%)9/202 (4.5%)102/202 (50.5%)
Placebo0/101 (0%)4/101 (4%)43/101 (42.6%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventEnlicitide DecanoatePlacebo
PneumoniaInfections and infestations4/2020/101
Angina pectorisCardiac disorders0/2021/101
Secondary adrenocortical insufficiencyEndocrine disorders0/2021/101
HaemorrhoidsGastrointestinal disorders0/2021/101
Oral infectionInfections and infestations0/2021/101
Device dislocationProduct Issues0/2021/101
Hypertensive crisisVascular disorders0/2021/101
DeathGeneral disorders1/2020/101
CholelithiasisHepatobiliary disorders1/2020/101
Hand fractureInjury, poisoning and procedural complications1/2020/101
Most frequent other events
Most frequent other events
EventEnlicitide DecanoatePlacebo
COVID-19Infections and infestations8/20211/101
NasopharyngitisInfections and infestations19/2028/101
InfluenzaInfections and infestations17/2029/101
NauseaGastrointestinal disorders16/2027/101
Accidental overdoseInjury, poisoning and procedural complications16/2024/101
HeadacheNervous system disorders16/2027/101
DiarrhoeaGastrointestinal disorders15/2022/101
DizzinessNervous system disorders14/2024/101
Upper respiratory tract infectionInfections and infestations10/2026/101
ArthralgiaMusculoskeletal and connective tissue disorders6/2026/101

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Enlicitide DecanoatePlaceboTotal
Mean52.9 ± 13.451.4 ± 13.952.4 ± 13.5
Sex: Female, Male
Sex: Female, Male(Participants)Enlicitide DecanoatePlaceboTotal
Female10847155
Male9454148
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Enlicitide DecanoatePlaceboTotal
Hispanic or Latino402464
Not Hispanic or Latino15673229
Unknown or Not Reported6410
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Enlicitide DecanoatePlaceboTotal
American Indian or Alaska Native000
Asian311950
Native Hawaiian or Other Pacific Islander000
Black or African American819
White14467211
More than one race191433
Unknown or Not Reported000
Baseline Low-density Lipoprotein Cholesterol (LDL-C)
Baseline Low-density Lipoprotein Cholesterol (LDL-C)(mg/dL)Enlicitide DecanoatePlaceboTotal
Mean120.7 ± 38.2115.6 ± 46.1119.0 ± 41.0
08

Study locations

59 sites
  • Alliance for Multispecialty Research, LLC ( Site 0023)
    Daphne, Alabama 36526, United States
  • Excel Medical Clinical Trials ( Site 0008)
    Boca Raton, Florida 33434, United States
  • Advanced Pharma Research ( Site 0007)
    Cutler Bay, Florida 33189, United States
  • Progressive Medical Research ( Site 0021)
    Port Orange, Florida 32127, United States
  • Clinical Site Partners LLC, dba CSP Orlando ( Site 0028)
    Winter Park, Florida 32789, United States
  • Synexus Clinical Research US - Evansville ( Site 0031)
    Evansville, Indiana 47714, United States
  • Franciscan Physician Network - Indiana Heart Physicians ( Site 0040)
    Indianapolis, Indiana 46237, United States
  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division ( Site 0001)
    Troy, Michigan 48098, United States
  • Velocity Clinical Research at The Pioneer Heart Institute, Lincoln ( Site 0026)
    Lincoln, Nebraska 68506, United States
  • Jubilee Clinical Research ( Site 0030)
    Las Vegas, Nevada 89106, United States
  • Wake Forest Baptist Health-Cardiovascular Medicine ( Site 0041)
    Winston-Salem, North Carolina 27157, United States
  • Velocity Clinical Research, Salt Lake City ( Site 0004)
    West Jordan, Utah 84088, United States
  • Health Research of Hampton Roads, Inc. ( Site 0020)
    Newport News, Virginia 23606, United States
  • Royal Prince Alfred Hospital-6West CV Ambulatory Care ( Site 2808)
    Camperdown, New South Wales 2050, Australia
  • Victorian Heart Hospital-Monash Cardiovascular Research Centre (MCRC) ( Site 2803)
    Clayton, Victoria 3168, Australia
  • Universidade Federal Do Ceara ( Site 0702)
    Fortaleza, Ceará 60430-270, Brazil
  • Instituto Dante Pazzanese de Cardiology-Fundação Adib Jatene ( Site 0701)
    São Paulo, São Paulo 04012-909, Brazil
  • Incor - Instituto do Coracao ( Site 0703)
    São Paulo, 05403-000, Brazil
  • Ecogene-21 ( Site 0510)
    Chicoutimi, Quebec G7H 7K9, Canada
  • Institut de Cardiologie de Montreal ( Site 0506)
    Montreal, Quebec H1T 1C8, Canada
  • Diex Recherche Trois-Rivieres ( Site 0513)
    Trois-Rivières, Quebec G9A 4P3, Canada
  • Clinical Research Chile SpA ( Site 0804)
    Valdivia, Los Ríos Region 5110683, Chile
  • CDIEM ( Site 0814)
    Providencia, Region M. de Santiago 7500859, Chile
  • Enroll SpA ( Site 0803)
    Santiago, Region M. de Santiago 7500587, Chile
  • Pontificia Universidad Catolica de Chile-CICUC ( Site 0812)
    Santiago, Region M. de Santiago 8330034, Chile
  • Fundación Centro de Investigación Clínica CIC ( Site 0906)
    Medellín, Antioquia 050021, Colombia
  • Ciensalud Ips S A S ( Site 0903)
    Barranquilla, Atlántico 08001, Colombia
  • Clinica de la Costa S.A.S. ( Site 0902)
    Barranquilla, Atlántico 080020, Colombia
  • Salud SURA Calle 100 ( Site 0918)
    Bogotá, Cundinamarca 110231, Colombia
  • Fakultní nemocnice Brno Bohunice-Interni kardiologicka klinika ( Site 3602)
    Brno, Brno-mesto 625 00, Czechia
  • Institut Klinicke a Experimentalni Mediciny ( Site 3601)
    Prague, Praha 4 140 21, Czechia
  • Fakultni Nemocnice u sv. Anny v Brne ( Site 3604)
    Brno, South Moravian 60200, Czechia
  • Meilahden tornisairaala - Meilahti Tower Hospital ( Site 1300)
    Helsinki, Uusimaa 00290, Finland
  • Queen Mary Hospital-Medical ( Site 3300)
    Pok Fu Lam, Hong Kong
  • Prince of Wales Hospital ( Site 3304)
    Shatin, NT, Hong Kong
  • Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ-Belgyógyászati Klinika ( Site 1603)
    Szeged, Csongrád megye 6725, Hungary
  • Semmelweis Egyetem-Városmajori Szív- és Érgyógyászati Klinika ( Site 1600)
    Budapest, 1122, Hungary
  • Debreceni Egyetem Klinikai Kozpont-Belgyógyászati Klinika (Anyagcsere Tanszék) ( Site 1601)
    Debrecen, 4032, Hungary
  • Shaare Zedek Medical Center ( Site 1710)
    Jerusalem, 9103102, Israel
  • Hadassah Medical Center ( Site 1709)
    Jerusalem, 9112001, Israel
  • Rabin Medical Center ( Site 1717)
    Petah Tikva, 4941492, Israel
  • Clalit Health Services - Sakhnin Community Clinic-Research Unit ( Site 1700)
    Sakhnin, 308100, Israel
  • Radboudumc-internal medicine ( Site 1952)
    Nijmegen, Gelderland 6525 GA, Netherlands
  • Amsterdam UMC, locatie AMC-Vascular Medicine Clin Trial Unit ( Site 1954)
    Amsterdam, North Holland 1105 AZ, Netherlands
  • Vasculair Onderzoek Centrum Hoorn ( Site 1953)
    Hoorn, North Holland 1625 HV, Netherlands
  • Universitair Medisch Centrum Utrecht-Vascular Medicine Research ( Site 1955)
    Utrecht, 3584 CX, Netherlands
  • Pacific Clinical Research Network - Rotorua ( Site 2902)
    Rotorua, Bay of Plenty 3010, New Zealand
  • New Zealand Clinical Research (Christchurch) ( Site 2901)
    Christchurch, Canterbury 8011, New Zealand
  • Nordlandssykehuset ( Site 2001)
    Bodø, Nordland 8005, Norway
  • Oslo Universitetssykehus Aker-Lipidklinikken ( Site 2000)
    Oslo, 0316, Norway
  • National University Hospital-Department of Medicine ( Site 3212)
    Singapore, Central Singapore 119074, Singapore
  • Changi General Hospital ( Site 3211)
    Singapore, Central Singapore 529889, Singapore
  • Hospital de Sant Joan Despí Moisès Broggi ( Site 2335)
    Sant Joan Despí, Catalonia 08970, Spain
  • SALUT SANT JOAN DE REUS-BAIX CAMP (EDP)-Vascular and Metabolism Unit ( Site 2329)
    Reus, Tarragona 43204, Spain
  • HOSPITAL CLINICO DE VALENCIA ( Site 2321)
    Valencia, Valenciana, Comunitat 46010, Spain
  • Mackay Memorial Hospital -Tamshui Branch ( Site 3109)
    New Taipei City, New Taipei 251, Taiwan
  • Shin Kong Wu Ho-Su Memorial Hospital ( Site 3106)
    Taipei City, Taipei 111, Taiwan
  • National Cheng Kung University Hospital-Internal Medicine ( Site 3107)
    Tainan, 704, Taiwan
  • National Taiwan University Hospital ( Site 3100)
    Taipei, 10002, Taiwan
09

References and documents

Publications

  • Ballantyne CM, Gellis L, Tardif JC, Banka P, Navar AM, Asprusten EA, Scott R, Stroes ESG, Froman S, Mendizabal G, Wang F, Catapano AL. Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial. JAMA. 2026 Jan 13;335(2):129-139. doi: 10.1001/jama.2025.20620. PubMed 41206969 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Apr 2025, 19 months.

Results were first posted in Feb 2026, 10 months after primary completion.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 19 months is close to that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2023
First posted
Jul 19, 2023
StartActual
Aug 8, 2023
Primary completionActual
Apr 7, 2025
CompletionActual
Apr 7, 2025
Results first posted
Feb 24, 2026
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05952869
Responsible party
Sponsor
First posted
Jul 19, 2023
Start date
Aug 8, 2023
Primary completion
Apr 7, 2025
Completion
Apr 7, 2025
Results posted
Feb 24, 2026
Last update
Feb 24, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-0616

Start the discussion